Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 800 participants.
Also called NCT02808351
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 800 participants
- Registry
-
NCT02808351
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02808351. Randomized; single masking; primary purpose treatment. Start 2016-07 (actual); primary completion 2021-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes
- Condition
- Diabetes Mellitus
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Berberine
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
Record details
- Record id
cardio:ct-nct02808351- Content hash
9f33b5303fd73082e98fda67da003d38092a23c6103f8c7b9a82dc507fe59b16